| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
| US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
Exkivity is owned by Takeda Pharms Usa.
Exkivity contains Mobocertinib Succinate.
Exkivity has a total of 2 drug patents out of which 0 drug patents have expired.
Exkivity was authorised for market use on 15 September, 2021.
Exkivity is available in capsule;oral dosage forms.
Exkivity can be used as treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Drug patent challenges can be filed against Exkivity from 15 September, 2025.
The generics of Exkivity are possible to be released after 13 May, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2026 |
| Orphan Drug Exclusivity(ODE-374) | Sep 15, 2028 |
Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient
NCE-1 date: 15 September, 2025
Market Authorisation Date: 15 September, 2021
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...
Dosage: CAPSULE;ORAL
EXKIVITY family patents
